Metropolitan Life Insurance Company (MetLife)’s Relay Therapeutics RLAY Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,222	Closed	-$43.3K	–	1681
2024 Q1	$43.3K	Hold	5,222	–	–	﹤0.01%	1481
2023 Q4	$57.5K	Hold	5,222	–	–	﹤0.01%	1372
2023 Q3	$43.9K	Buy	5,222 +384	+8%	+$4.13K	﹤0.01%	1481
2023 Q2	$60.8K	Hold	4,838	–	–	﹤0.01%	1312
2023 Q1	$79.7K	Sell	4,838 -426	-8%	-$7.64K	﹤0.01%	1122
2022 Q4	$78.6K	Buy	5,264 +706	+15%	+$13.5K	﹤0.01%	1202
2022 Q3	$102K	Hold	4,558	–	–	﹤0.01%	1007
2022 Q2	$76.3K	Hold	4,558	–	–	﹤0.01%	1224
2022 Q1	$136K	Sell	4,558 -13,536	-75%	-$328K	﹤0.01%	1009
2021 Q4	$556K	Buy	18,094 +1,810	+11%	+$57.2K	0.01%	1357
2021 Q3	$513K	Hold	16,284	–	–	0.01%	1444
2021 Q2	$596K	Buy	16,284 +3,453	+27%	+$114K	0.01%	1403
2021 Q1	$444K	Buy	12,831 +3,406	+36%	+$148K	0.01%	1499
2020 Q4	$392K	Hold	9,425	–	–	0.01%	1521
2020 Q3	$401K	Buy	+9,425	New	+$359K	0.01%	1362

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Metropolitan Life Insurance Company (MetLife)'s RLAY Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 5,222 shares — an estimated $43.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RLAY in Q3 2020 and held it in 15 quarters. The position peaked at $596K in Q2 2021. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 5,222 Relay Therapeutics shares in Q2 2024, an estimated $43.3K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Relay Therapeutics in Q3 2020 and held it in 15 quarters.
Metropolitan Life Insurance Company (MetLife)'s Relay Therapeutics position peaked at $596K in Q2 2021.
178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.